Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS
I'm PortAI, I can summarize articles.
Elicio Therapeutics announced interim results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P, showing 87% of patients had T cell responses to tumor neoantigens beyond mKRAS. This suggests ELI-002 7P may broaden immune responses to include personalized tumor antigens. The findings align with previous Phase 1 data and were presented in a recent company announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments